NCT00364949

Brief Summary

Polycystic ovary syndrome (PCOS) is among the most common endocrine disorders in premenopausal women, affecting 7-10% of this population. This syndrome is characterized by elevated levels of testosterone and chronic anovulation, and frequently of obesity. This study is designed to test the hypothesis that there is in utero testosterone excess, altered insulin secretion, and/or intrauterine growth retardation in the female offspring of women with PCOS. The allele 8 can be used to identify the reproductive and metabolic abnormalities associated with PCOS. This study will determine whether allele 8 positive \[A8(+)\] female offspring have more profound changes in these parameters compared to A8(-) female offspring. Androgen and insulin levels in amniotic fluid from pregnant women with PCOS will be compared to levels in pregnant control women. Androgen and insulin levels in cord blood will also be measured. Further, gestational age and anthropomorphic measurements in offspring of women with PCOS will be assessed and compared to that in offspring of matched control women. We will test the hypothesis that androgens are elevated in infancy in the female offspring of women with PCOS. We will assess sex steroids, insulin, and c-peptide levels in infants of PCOS women and compare them to the levels in infants of control women up to 1 year of age during the minipuberty of infancy. We will determine whether any of these parameters differ in A8(+) compared to A8(-) PCOS offspring.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2003

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2003

Completed
3.6 years until next milestone

First Submitted

Initial submission to the registry

August 15, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 16, 2006

Completed
4 years until next milestone

Results Posted

Study results publicly available

August 18, 2010

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2012

Completed
Last Updated

April 10, 2013

Status Verified

April 1, 2013

Enrollment Period

9.5 years

First QC Date

August 15, 2006

Results QC Date

July 19, 2010

Last Update Submit

April 3, 2013

Conditions

Keywords

Polycystic Ovary SyndromePCOSPregnantCord Blood

Outcome Measures

Primary Outcomes (7)

  • Estradiol Level in Female Offspring

    The blood that were analyzed were taken from cord blood and not from the offspring.

    One time sampling from the cord blood

  • Androstenedione Level in Female Offspring

    cord blood

  • Testosterone Level in Female Offspring

    cord blood

  • 17-hydroxyprogesterone Level in Female Offspring

    cord blood

  • Dihydrotestosterone Level in Female Offspring

    cord blood

  • Dehydroepiandrosterone Level in Female Offspring

    cord blood

  • Infant Birth Weight (Male and Female)

    birth

Eligibility Criteria

Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women with PCOS and control women and their offspring

You may not qualify if:

  • history of gestational diabetes mellitus, eclampsia, pre-eclampsia or any medical disorders complicating their pregnancies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northwestern University School of Medicine

Chicago, Illinois, 60611, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

blood

MeSH Terms

Conditions

Polycystic Ovary Syndrome

Condition Hierarchy (Ancestors)

Ovarian CystsCystsNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGonadal DisordersEndocrine System Diseases

Results Point of Contact

Title
Dr. Andrea Dunaif
Organization
Northwestern University

Study Officials

  • Andrea E Dunaif, MD

    Chief, Division of Endocrinology, Metabolism and Molecular Medicine

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
NIH
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Charles F Kettering Professor of Endocrinology & Metabolism Vice Chair for Research, Department of Medicine

Study Record Dates

First Submitted

August 15, 2006

First Posted

August 16, 2006

Study Start

January 1, 2003

Primary Completion

July 1, 2012

Study Completion

July 1, 2012

Last Updated

April 10, 2013

Results First Posted

August 18, 2010

Record last verified: 2013-04

Locations